Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Subjects between the ages of 20-45 with mild to moderate asthma will be recruited. Following
consent, subjects will undergo an evaluation to assure no underlying metabolic bone disease.
Individuals will be treated with inhaled fluticasone low or high dose, daily for 3 months.
Serum and urine biochemical markers of bone metabolism will be collected at baseline and
monthly for three months. Adherence to study medication and adverse events will be collected
at monthly intervals. Differences between fluticasone low and high dose treated individuals
will be analyzed between groups and compared with baseline values.